Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.

Alphabet’s addition to the Dow Jones on June 29 (replacing Verizon) highlights rising exposure to advertising, cloud, and AI, but the article’s key stock takeaways skew positive: Cisco Q3 FY2026 revenue rose 12% to $15.8B with net income up 35% to $3.4B, Coca-Cola Q1 revenue increased 12% to $12.5B with North America volume up 4%, and Amgen’s Q1 revenue grew 6% to $8.6B with EPS up 4% to $3.20 as its monthly-dosed obesity drug (MariTide) advances. Dividend appeal is emphasized across names: Cisco yield 1.5%, Coca-Cola 2.6% and Amgen 2.8%, alongside multiple-year dividend streaks.

Analysis

The only immediate market-moving piece here is the index-flow effect: GOOG gets a small, mechanical bid from benchmark ownership, while VZ loses a little marginal support. That is a days-to-weeks phenomenon, not a structural rerating; the real question is whether investors keep paying up for AI/cloud exposure even as capital intensity remains elevated. If GOOG cannot convert that spending into visible margin leverage over the next 1-2 quarters, the post-inclusion pop should fade.

CSCO looks like the cleaner second-order AI winner because networking spend usually lags compute deployment and can stay sticky even if the GPU cycle cools. That makes it a better “picks-and-shovels” expression than the pure AI leaders for the next 1-3 months, with the key falsifier being any slowdown in order commentary or a weaker backlog conversion rate. KO is more of a defensive cash-flow trade: the risk is not demand collapse, but that the market is already paying for perceived quality, so any North America volume slowdown or FX drag can cap multiple expansion quickly.

AMGN is the longest-dated setup and the most mispriced by consensus. MariTide is not a next-quarter earnings lever; it is a multi-year optionality trade against a market that is already rewarding the dividend and visible base business. The upside is a sharp re-rate if the drug proves meaningfully differentiated; the downside is that if efficacy or tolerability looks only average, the obesity premium disappears and the stock should revert to being valued mainly on cash returns.

Key Decisions for Investors

• Tactically long GOOG for 1-2 weeks into/after Dow index flows; treat as a small momentum trade, not a fundamental call. Add only on a pullback; invalidate if GOOG fails to outperform VZ on a relative basis within ~10 trading days.
• Initiate CSCO/VZ pair: long CSCO, short VZ, targeting 3-5% relative outperformance over 1-3 months. Thesis is AI/networking leverage versus low-growth telecom cash yield; cover if CSCO order growth decelerates or VZ stabilizes on a yield rotation.
• Small starter long AMGN, or better, a 6-18 month call spread if liquidity allows. This is a convex obesity optionality trade with a dividend floor; exit if MariTide data show no meaningful differentiation versus incumbent obesity therapies.
• Hold/overweight KO as a defensive compounder only if volumes stay positive into the next quarter. If North America volume rolls over, rotate out—the stock will likely trade like a bond proxy and lose upside torque.